Immudex ApS
Private limited companyCVR 31348854VirumActive
Immudex ApS is a private limited company, based in Virum, active in research and experimental development on natural sciences and engineering, founded in 2008. The company made a loss in both 2024 and 2025, most recently DKK 11m. With 35 employees, the company is about 7 times larger than the industry median. Equity fell to DKK 16.1m in 2025.
Key figures · financial year 2025
Gross profitDKK 22.7m−10% vs. 2024
Net profit−DKK 11m−55.2% vs. 2024
EquityDKK 16.1m−35.7% vs. 2024
Employees35latest month from CVR
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- Gross profit fell 10% (2024 → 2025), to DKK 22.7m.
- The loss grew: from DKK 7.1m to DKK 11m (2024 → 2025).
- Equity fell 36% (2024 → 2025), to DKK 16.1m.
Employees
- 13 fewer employees than a year earlier: 35 (08/2026) against 48 (08/2025).
Management and owners, last 24 months
- New in management: Hans Christian Barré Pedersen (board member, 03/11/2025) and Jamil El-Ali (board member, 03/11/2025).
- Stepped down: Helene Kähler Hjenner (board member, 03/11/2025).
Registrations, last 24 months
- 31/01/2026: Share capital changed from 740,349 DKK to 776,321 DKK
- 31/01/2025: Share capital changed from 725,927 DKK to 740,349 DKK
- 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2020–2025 · amounts in DKK thousandEquity and net profit
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | not stated | not stated | not stated | – |
| Gross profit | 15,280 | 24,389 | 18,938 | 29,872 | 25,173 | 22,665 | −10% |
| Operating profit (EBIT) | −2,260 | 698 | −10,509 | −1,489 | −9,612 | −10,988 | −14.3% |
| Profit before tax | −2,204 | 49 | −9,187 | −1,368 | −9,098 | −13,136 | −44.4% |
| Net profit | −1,671 | 754 | −6,769 | −1,092 | −7,106 | −11,025 | −55.2% |
| Total assets | 45,963 | 46,841 | 41,060 | 42,449 | 46,587 | 49,096 | +5.4% |
| Equity | 33,697 | 34,451 | 29,376 | 29,924 | 24,947 | 16,050 | −35.7% |
| Liabilities | 12,266 | 12,389 | 11,685 | 12,525 | 21,640 | 33,046 | +52.7% |
| Cash and cash equivalents | 7,804 | 15,266 | 5,875 | 5,640 | 6,359 | 5,294 | −16.7% |
| Average number of employees | 26 | 33 | 39 | 39 | 42 | 40 | −4.8% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresLoss for 4 years in a row
Net result has been negative in 2022–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
Equity fell sharply
Equity fell 36% from 2024 to 2025 (DKK 24.9m to DKK 16.1m).
How is this calculated?
Equity has fallen by at least 30% from the previous annual report, and it was positive the year before.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
6 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/07/2024 – 30/06/2025 | 13/11/2025 | The company | PDF not statedXBRL |
| 2024 | 01/07/2023 – 30/06/2024 | 25/11/2024 | The company | PDFXBRL |
| 2023 | 01/07/2022 – 30/06/2023 | 28/11/2023 | The company | PDFXBRL |
| 2022 | 01/07/2021 – 30/06/2022 | 06/12/2022 | The company | PDFXBRL |
| 2021 | 01/07/2020 – 30/06/2021 | 06/12/2021 | The company | PDFXBRL |
| 2020 | 01/07/2019 – 30/06/2020 | 09/12/2020 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Gross profitDKK 22.7mNo. 52 of 421
Better than 88% of the companies in the industry
EquityDKK 16.1mNo. 117 of 431
Better than 73% of the companies in the industry
Number of employees35No. 51 of 431
Better than 88% of the companies in the industry
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with 20–49 employees9,922 companies in the comparison | No. 2,327of 9,892 Better than 76% | No. 2,112of 9,922 Better than 79% |
| Same industry and 20–49 employees64 companies in the comparison | No. 13of 62 Better than 80% | No. 36of 64 Better than 44% |
| Companies that are between 15 and 29 years old24,910 companies in the comparison | No. 3,029of 24,791 Better than 88% | No. 5,067of 24,909 Better than 80% |
| All companies of type ApS66,508 companies in the comparison | No. 2,080of 66,379 Better than 97% | No. 4,930of 66,505 Better than 93% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineeringGross profit
- Immudex ApSDKK 22.7m
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
Net profit
- Immudex ApS−DKK 11m
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
Equity
- Immudex ApSDKK 16.1m
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
Employees
- Immudex ApS35
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership RegisterOwners
- Viggo Harboe 2006 Holding ApS50%
- Hjeca Holding i ApS5%
- Gunnersen Marker Holding ApS20%
Immudex ApS
Management
5 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Patrik Olof Dahlén | CEO | 15/11/2022 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Søren Elmann Ingerslev | Chair of the board | 14/11/2014 |
| Douglas Frank Sweet | Board member | 14/11/2014 |
| Hans Christian Barré Pedersen | Board member | 03/11/2025 |
| Jamil El-Ali | Board member | 03/11/2025 |
- Founders
- ApS KBUS 38 nr.3117
Former management (14)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Peter Andreas Stakemann | Chair of the board | 01/04/2008 | 09/06/2008 |
| Peter Andreas Stakemann | Director | 01/04/2008 | 09/06/2008 |
| Henrik Pedersen | Chair of the board | 09/06/2008 | 09/06/2008 |
| Henrik Pedersen | Director | 09/06/2008 | 09/06/2008 |
| Jørgen Schøller | Board member | 09/06/2008 | 29/06/2009 |
| Henrik Pedersen | Director | 09/06/2008 | 06/02/2017 |
| Jørgen Axel Thorball | Chair of the board | 29/06/2009 | 14/11/2014 |
| Henrik Pedersen | Board member | 29/06/2009 | 14/11/2014 |
| Andrew David Gardiner | Board member | 19/09/2009 | 14/11/2014 |
| Patrik Olof Dahlén | Board member | 14/11/2014 | 30/11/2022 |
| Poul Valentin Hansen | Board member | 14/11/2014 | 06/02/2017 |
| Søren Elmann Ingerslev | Director | 06/02/2017 | 20/02/2017 |
| Helene Kähler Hjenner | CEO | 20/02/2017 | 15/11/2022 |
| Helene Kähler Hjenner | Board member | 30/11/2022 | 03/11/2025 |
Signing rule: Selskabet tegnes af en direktør i forening med bestyrelsens formand eller af to bestyrelsesmedlemmer i forening.
Address and production units
1 active production unitsBredevej 2A
2830 Virum
| Production unit | Address | Employees | P number |
|---|---|---|---|
| IMMUDEX ApS | Bredevej 2A, 2830 Virum | 35 | 1014323844 |
Purpose
Selskabets formål er kommercialisering af immunmonitorerings metoder
The purpose is quoted from the register in Danish.
Changes year by year
76 registered events72015
02016
102017
02018
02019
52020
12021
62022
22023
22024
62025
12026
20261 changecapital 1
- CapitalShare capital changed from 740,349 DKK to 776,321 DKK
20256 changesaccounts 1 · management 3 · capital 1 · industry 1
- AccountsAnnual report for 2025 published
- ManagementJamil El-Ali appointed board member
- ManagementHans Christian Barré Pedersen appointed board member
- ManagementHelene Kähler Hjenner stepped down as board member
- CapitalShare capital changed from 725,927 DKK to 740,349 DKK
- IndustryIndustry changed to Research and experimental development on natural sciences and engineering (721000)
20242 changesaccounts 1 · capital 1
- AccountsAnnual report for 2024 published
- CapitalShare capital changed from 711,505 DKK to 725,927 DKK
20232 changesaccounts 1 · capital 1
- AccountsAnnual report for 2023 published
- CapitalShare capital changed from 700,136 DKK to 711,505 DKK
20226 changesaccounts 1 · management 4 · capital 1
- AccountsAnnual report for 2022 published
- ManagementHelene Kähler Hjenner appointed board member
- ManagementPatrik Olof Dahlén stepped down as board member
- ManagementPatrik Olof Dahlén appointed ceo
- ManagementHelene Kähler Hjenner stepped down as ceo
- CapitalShare capital changed from 688,667 DKK to 700,136 DKK
20211 changeaccounts 1
- AccountsAnnual report for 2021 published
20205 changesaccounts 1 · capital 1 · ownership 2 · address 1
- AccountsAnnual report for 2020 published
- CapitalShare capital changed from 536,124 DKK to 688,667 DKK
- OwnershipGUNNERSEN MARKER HOLDING ApS registered as owner (20%)
- OwnershipGUNNERSEN MARKER HOLDING ApS is no longer registered as owner
- AddressMoved to Bredevej 2A, 2830 Virum
201710 changesmanagement 5 · ownership 4 · capital 1
- ManagementHelene Kähler Hjenner appointed ceo
- ManagementSøren Elmann Ingerslev stepped down as director
- OwnershipHJECA HOLDING I ApS registered as owner (5%)
- ManagementSøren Elmann Ingerslev appointed director
- ManagementPoul Valentin Hansen stepped down as board member
- ManagementHenrik Pedersen stepped down as director
- OwnershipVIGGO HARBOE 2006 HOLDING ApS registered as owner (50%)
- OwnershipCHEMGENE ApS is no longer registered as owner
- OwnershipVIGGO HARBOE 2006 HOLDING ApS is no longer registered as owner
- CapitalShare capital changed from 479,340 DKK to 536,124 DKK
20157 changescapital 1 · ownership 6
- CapitalShare capital changed from 430,306 DKK to 479,340 DKK
- OwnershipCHEMGENE ApS registered as owner (10%)
- OwnershipVIGGO HARBOE 2006 HOLDING ApS registered as owner (33.33%)
- OwnershipHJECA HOLDING I ApS is no longer registered as owner
- OwnershipCHEMGENE ApS is no longer registered as owner
- OwnershipVIGGO HARBOE 2006 HOLDING ApS is no longer registered as owner
- OwnershipHJECA HOLDING I ApS registered as owner (5%)
201411 changesownership 3 · capital 1 · management 7
- OwnershipCHEMGENE ApS registered as owner (15%)
- CapitalShare capital changed from 377,460 DKK to 430,306 DKK
- ManagementPatrik Olof Dahlén appointed board member
- ManagementPoul Valentin Hansen appointed board member
- ManagementSøren Elmann Ingerslev appointed chair of the board
- ManagementDouglas Frank Sweet appointed board member
- ManagementAndrew David Gardiner stepped down as board member
- ManagementJørgen Axel Thorball stepped down as chair of the board
- ManagementHenrik Pedersen stepped down as board member
- OwnershipGUNNERSEN MARKER HOLDING ApS registered as owner (25%)
- OwnershipVIGGO HARBOE 2006 HOLDING ApS registered as owner (25%)
20131 changecapital 1
- CapitalShare capital changed from 374,460 DKK to 377,460 DKK
20111 changecapital 1
- CapitalShare capital changed from 357,522 DKK to 374,460 DKK
20101 changecapital 1
- CapitalShare capital changed from 193,088 DKK to 357,522 DKK
200910 changescapital 2 · address 2 · management 4 · industry 1 · name 1
- CapitalShare capital changed from 152,438 DKK to 193,088 DKK
- AddressMoved to Fruebjergvej 3, 2100 København Ø
- ManagementAndrew David Gardiner appointed board member
- AddressMoved to Produktionsvej 42, 2600 Glostrup
- IndustryIndustry changed to Forskning og eksperimentel udvikling indenfor bioteknologi (721100)
- NameName changed from INITIO ApS to IMMUDEX ApS
- CapitalShare capital changed from 125,000 DKK to 152,438 DKK
- ManagementJørgen Axel Thorball appointed chair of the board
- ManagementHenrik Pedersen appointed board member
- ManagementJørgen Schøller stepped down as board member
200812 changesaddress 1 · name 1 · management 9 · founded 1
- AddressMoved to Lynge Bygade 12, d, 3540 Lynge
- NameName changed from ApS KBIL 17 NR. 2544 to INITIO ApS
- ManagementHenrik Pedersen appointed chair of the board
- ManagementHenrik Pedersen stepped down as chair of the board
- ManagementHenrik Pedersen appointed director
- ManagementHenrik Pedersen stepped down as director
- ManagementJørgen Schøller appointed board member
- ManagementPeter Andreas Stakemann stepped down as director
- ManagementPeter Andreas Stakemann stepped down as chair of the board
- FoundedRegistered as ApS KBIL 17 NR. 2544
- ManagementPeter Andreas Stakemann appointed director
- ManagementPeter Andreas Stakemann appointed chair of the board
Related companies
Same industry in Lyngby-Taarbæk
- Thales Aerospace Communications Lyngby ApS52 employees
- Capres A/S34 employees
- Mdsi ApS33 employees
- Novo Nordisk Foundation Cellerator A/S33 employees
- Bifrost Communications ApS9 employees
- Mycoverse ApS9 employees
Same people in management
- Pure Gym Denmark A/Svia Peter Andreas Stakemann
- Atea A/Svia Peter Andreas Stakemann
- Bone's Restauranter A/Svia Søren Elmann Ingerslev
- Leo Pharma A/Svia Patrik Olof Dahlén
- Molslinjen A/Svia Søren Elmann Ingerslev
- SATS Danmark A/Svia Søren Elmann Ingerslev
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.